Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Alessandro, Paniccia, Ana L, Gleisner, Mazen S, Zenati, Amr I, Al Abbas, Jae Pil, Jung, Nathan, Bahary, Kenneth K W, Lee, David, Bartlett, Melissa E, Hogg, Herbert J, Zeh, Amer H, Zureikat
Publikováno v:
Annals of surgical oncology. 27(8)
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Nathan Bahary, Caroline J. Rieser, Herbert J. Zeh, Mazen S. Zenati, Kenneth K. Lee, Amer H. Zureikat, Hao Liu, Aatur D. Singhi, Amr Al-abbas, Melissa E. Hogg
Publikováno v:
Ann Surg Oncol
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for f
Autor:
Matthew P. Holtzman, Melissa E. Hogg, J. Wallis Marsh, David L. Bartlett, James F. Pingpank, Mashaal Dhir, Amer H. Zureikat, David A. Geller, M. Haroon A. Choudry, Herbert J. Zeh, Heather L. Jones, Mazen S. Zenati, Nathan Bahary, Allan Tsung
Publikováno v:
Annals of Surgical Oncology. 25:550-557
In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver me
Autor:
Matthew P. Holtzman, Amer H. Zureikat, Melanie Ongchin, David L Bartlett, Caroline J. Rieser, James F. Pingpank, Andrew Lee, Mazen S. Zenati, M. Haroon A. Choudry, Richard S. Hoehn, Eliza Kang, Lauren B Hall
Publikováno v:
Annals of Surgical Oncology. 28:875-875
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS HIPEC) can offer significant survival advantage for select patients with colorectal peritoneal metastases (CRPM). Low socioeconomic status (SES) is implicated in disparities i
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Autor:
Amer H. Zureikat, Amr I. Al Abbas, Melissa E. Hogg, Herbert J. Zeh, Jae Pil Jung, Ahmad Hamad, Caroline J. Rieser, Mazen S. Zenati
Publikováno v:
Annals of Surgical Oncology. 27:965-965
In the original article, Caroline J. Rieser’s last name is spelled wrong. It is correct as reflected here.